Soriano LJ, Rojas AP

Idioma: Ingles.
Referencias bibliográficas: 5
Paginas: 1-2
Archivo PDF: 169.75 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-and update on the status. Military Med Research. [internet] 2020 March 16 [cited 1 April 2020];7:11. Available from: http://www.dx.doi.org/10.1186/s40779-020-00240-0

2. Gao J, Tian Z, Yang X. Breakthrough:chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends [internet] 2020 Feb 19 [cited 1 April 2020]. Available from: http://www.dx.doi.org/10.5582/bst.2020.01047

3. Ko WC, Rolain JM, Lee NY, Chen PL, Huang CT, Lee PI, et al. Arguments in favour of remdesivir for treating SARS/CoV/2 infections. Int J Antimicrob Agents. [internet] 2020 March 16 [cited 1 April 2020]. Available from: http://www.dx.doi.org/10.1016/j.ijantimicag.2020.105933

4. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. New Engl J Med. [internet] 2020 Jan 31 [cited 1 April 2020]. Available from: http://www.dx.doi.org/10.1056/NEJMoa2001191

5. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. New Engl J Med. [internet] 2020 March 18 [cited 1 April 2020]. Available from: http://www.dx.doi.org/10.1056/NEJMoa2001282